Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Author:
Publisher
Elsevier BV
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference30 articles.
1. Combination therapies for COVID-19: an overview of the clinical trials landscape;Akinbolade;Br J Clin Pharmacol,2022
2. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report;Gandhi;Nat Commun,2022
3. Sanderson T, Hisner R, Donovan-Banfield Ia, Peacock T, Ruis C. Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases. medRxiv. 27 January 2023. https://www.medrxiv.org/content/10.1101/2023.01.26.23284998v1 [accessed 24 October 2023]
4. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters;Abdelnabi;Front Pharmacol,2022
5. Molnupiravir in combination with remdesivir for severe COVID-19 patients admitted to hospital: a case series;Hashemian;Microbes. Infect Chemother,2022
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model;Antiviral Research;2024-11
2. Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases;Biomedicine & Pharmacotherapy;2024-09
3. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19;Expert Opinion on Biological Therapy;2024-08-02
4. The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19;Seminars in Hematology;2024-08
5. Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series;Open Forum Infectious Diseases;2024-07-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3